SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, today announced a manufacturing agreement for ATYR1923, aTyr Pharmas lead therapeutic candidate that is currently in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).

aTyr Pharma, Inc. (NASDAQ:LIFE) Short Interest Update

07:00pm, Friday, 19'th Nov 2021 Dakota Financial News
aTyr Pharma, Inc. (NASDAQ:LIFE) was the target of a large decline in short interest in October. As of October 29th, there was short interest totalling 793,800 shares, a decline of 34.4% from the October 14th total of 1,210,000 shares. Based on an average daily trading volume, of 5,350,000 shares, the short-interest ratio is presently 0.1 […]

aTyr Pharma (NASDAQ:LIFE) Raised to Buy at Zacks Investment Research

11:12am, Friday, 19'th Nov 2021 Transcript Daily
Zacks Investment Research upgraded shares of aTyr Pharma (NASDAQ:LIFE) from a hold rating to a buy rating in a research report released on Tuesday, Zacks.com reports. They currently have $9.75 price target on the biotechnology companys stock. According to Zacks, aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and []

aTyr Pharma (NASDAQ:LIFE) Downgraded to Hold at Zacks Investment Research

06:26am, Wednesday, 17'th Nov 2021 Dakota Financial News
aTyr Pharma (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr []
The mean of analysts' price targets for Atyr Pharma (LIFE) points to an 111.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an
The mean of analysts' price targets for Atyr Pharma (LIFE) points to an 111.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an

FY2025 EPS Estimates for aTyr Pharma, Inc. Raised by Analyst (NASDAQ:LIFE)

08:48am, Monday, 15'th Nov 2021 Dakota Financial News
aTyr Pharma, Inc. (NASDAQ:LIFE) Analysts at Oppenheimer raised their FY2025 earnings per share (EPS) estimates for aTyr Pharma in a research report issued to clients and investors on Thursday, November 11th. Oppenheimer analyst H. Singh now forecasts that the biotechnology company will post earnings per share of $0.22 for the year, up from their []
Equities research analysts expect aTyr Pharma, Inc. (NASDAQ:LIFE) to post sales of $6.75 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for aTyr Pharmas earnings, with the lowest sales estimate coming in at $3.50 million and the highest estimate coming in at $10.00 million. aTyr Pharma posted sales of []
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2021 Results - Earnings Call Transcript
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 20.75% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Investors need to pay close attention to aTyr Pharma (LIFE) stock based on the movements in the options market lately.
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological path
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological path
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE